Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.
No summary available
The stock appears fairly valued based on recent earnings. The current price of $25.34 is near the lower end of the recent trading range and essentially at the calculated fundamental target price of $25.16. Valuation multiples (P/E ~19x, P/B ~1.6x, P/S ~2.3x) are within reasonable historical ranges for a large-cap pharmaceutical company with single-digit earnings growth prospects.
